Explore publications and presentations that bring our science to life.

Download our Latest Non-confidential Investor Presentation

Download our mRNA Engineered Cell & Cytokine Medicines Presentation

IRX-2, a novel immunotherapeutic, protects human T cells from tumor-induced cell death

Czystowska M, Han J, Szczepanski MJ, et al. Cell Death Differ. 2009;16(5):708-718.

Mechanisms of T-cell protection from death by IRX-2: a new immunotherapeutic

Czystowska M, Szczepanski MJ, Szajnik M, et al. Cancer Immunol Immunother. 2011;60(4):495-506.

IRX-2, a novel in vivo immunotherapeutic, induces maturation and activation of human dendritic cells in vitro

Egan JE, Quadrini KJ, Santiago-Schwarz F, Hadden JW, Brandwein HJ, Signorelli KL. J Immunother. 2007;30(6):624-633.

IRX-2, a novel immunotherapeutic, enhances functions of human dendritic cells

Schilling B, Harasymczuk M, Schuler P, Egan J, Ferrone S, Whiteside TL. PLoS One. 2013;8(2):e47234.

IRX-2, a novel biologic, favors the expansion of T effector over T regulatory cells in a human tumor microenvironment model

Schilling B, Harasymczuk M, Schuler P, Egan JE, Whiteside TL. J Mol Med (Berl). 2012;90(2):139-147.

IRX-2, a novel immunotherapeutic, enhances and protects NK-cell functions in cancer patients.

Schilling B, Halstead ES, Schuler P, Harasymczuk M, Egan JE, Whiteside TL. Cancer Immunol Immunother. 2012;61(9):1395-1405.

IRX-2 increases the T cell-specific immune response to protein/peptide vaccines.

Naylor PH, Hernandez KE, Nixon AE, et al. Vaccine. 2010;28(43):7054-7062

Peptide based vaccine approaches for cancer—a novel approach using a WT-1 synthetic long peptide and the IRX-2 immunomodulatory regimen.

Naylor PH, Egan JE, Berinstein NL. Cancers (Basel). 2011;3(4):3991-4009.